Tumor Mutational Burden Guides Therapy in a Treatment Refractory

Publication Title

The oncologist

Authors

Munveer S Bhangoo
Peter Boasberg
Pareen Mehta
Julia A Elvin
Siraj M Ali
Winnie Wu, Department of Pathology, John Wayne Cancer Institute, Providence Saint John's Medical Center, Los Angeles, California, USA.Follow
Samuel J Klempner

Document Type

Article

Publication Date

5-1-2018

Abstract

Gynecologic carcinosarcomas, previously known as malignant mixed Müllerian tumors, are uncommon malignancies that demonstrate an aggressive biology and lack a standard therapeutic approach. Molecular analyses have revealed recurrent alterations in chromatin remodeling genes, but clinical support for therapeutic significance is lacking. We prospectively identified a patient with refractory uterine carcinosarcoma whose tumor was subject to molecular profiling at diagnosis and again at radiographic progression. Initial molecular testing did not assess tumor mutational burden, DNA polymerase ɛ (

KEY POINTS: Uterine carcinosarcoma is an uncommon and aggressive histologic variant of endometrial carcinoma with a poor prognosis.Inactivating DNA polymerase ɛ (

Clinical Institute

Cancer

Specialty/Research Institute

Oncology